For decades, aspirin has been the gold standard for preventing second heart attacks and strokes. However, novel long-term data suggests a shift in that paradigm for patients who have undergone percutaneous coronary intervention (PCI) with drug-eluting stents. The 10-year follow-up results of the HOST-EXAM trial indicate that clopidogrel vs. Aspirin monotherapy at 10 years post PCI favors clopidogrel for reducing major cardiovascular events and bleeding.
The study, presented as featured clinical research at the ACC.26 annual scientific session and published in The Lancet, tracked 5,438 patients across 37 sites in South Korea. After completing an initial period of dual antiplatelet therapy (DAPT), patients were randomized to receive either clopidogrel or aspirin as a single agent. Over a median follow-up of 10.5 years, those taking clopidogrel showed a significantly lower risk of a composite endpoint including all-cause death, nonfatal myocardial infarction (MI), stroke, and major bleeding.
As a physician, I find the most compelling aspect of this data is not just the reduction in thrombotic events—such as stent thrombosis or ischemic stroke—but the simultaneous reduction in bleeding. Typically, in cardiovascular medicine, increasing the efficacy of a blood thinner increases the risk of hemorrhage. The HOST-EXAM findings suggest that clopidogrel may offer a superior balance of safety and efficacy for long-term secondary prevention.
Breaking Down the 10-Year Clinical Outcomes
The trial focused on patients who had successfully completed 6 to 18 months of DAPT without adverse events. The primary goal was to determine which single-agent therapy provided the best long-term protection during the chronic maintenance phase of recovery. The results showed a clear divergence in outcomes between the two cohorts.
The composite primary endpoint—a combination of all-cause death, nonfatal MI, stroke, and readmission for acute coronary syndrome (ACS)—occurred in 25.4% of the clopidogrel group compared to 28.5% of the aspirin group, representing a hazard ratio of 0.86. While all-cause mortality remained similar between both groups, the clopidogrel cohort experienced fewer thrombotic events and lower rates of any bleeding.
| Endpoint | Clopidogrel (75 mg daily) | Aspirin (100 mg daily) |
|---|---|---|
| Composite Primary Endpoint | 25.4% | 28.5% |
| Thrombotic Endpoint* | 17.3% | 20% |
| Any Bleeding | 9.1% | 10.8% |
*Thrombotic endpoint includes cardiovascular death, ischemic stroke, ACS readmission, and stent thrombosis.
Who Benefits Most From This Shift?
While the benefit of clopidogrel was consistent across most patient subgroups, the researchers noted a potentially greater benefit among patients with chronic kidney disease. This is a critical finding, as these patients often face a more complex risk profile regarding both clotting and bleeding.
The study also highlighted a practical advantage: treatment adherence. Patients assigned to clopidogrel were more likely to stick to their medication regimen over the decade than those assigned to aspirin. This suggests that the tolerability of clopidogrel may be higher in a real-world, long-term setting.
The implications are particularly significant for younger patients. In an accompanying editorial in The Lancet, Drs. Mauro Chiarito and Francesco Tartaglia noted that this is the first study to provide such a long-term comparison, making the findings “particularly relevant for young patients with a long life expectancy.”
The Economic and Clinical Rationale
Beyond the clinical data, the cost of treatment plays a role in public health. Dr. Jeehoon Kang and his team emphasized that the substantial reduction in the cost of clopidogrel over the last 30 years, paired with these long-term results, justifies a “reappraisal” of the drug’s benefits over aspirin.
For many years, aspirin was the default because of its low cost and widespread availability. However, as clopidogrel has become more affordable and its long-term superiority in this specific population has been documented, the clinical argument for its use as the preferred agent for maintenance therapy after PCI has strengthened.
What This Means for Future Guidelines
Despite the strong 10-year data, the medical community is cautious about an immediate, universal change in prescribing habits. The researchers and editorialists agree that while these results may contribute to a future shift in clinical guideline recommendations, more evidence is needed.
The primary constraint of the HOST-EXAM trial is its geography; it was conducted exclusively at sites across South Korea. Because different populations can respond differently to antiplatelet agents due to genetic variations—specifically in how the liver activates clopidogrel—larger randomized controlled trials (RCTs) in more diverse global populations are essential.
Until those diverse trials are completed, the “preferred” status of clopidogrel remains a strong suggestion based on high-quality data rather than a definitive global mandate. Patients are encouraged to discuss their specific risk factors, including kidney function and bleeding history, with their cardiologist to determine the best monotherapy path.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The next step for the cardiology community will be the integration of these findings into updated society guidelines, likely following further analysis of diverse patient cohorts in subsequent global studies. We will continue to monitor the updates from the American College of Cardiology and the European Society of Cardiology regarding changes to antiplatelet maintenance protocols.
Do you have questions about the latest heart health research? Share your thoughts in the comments or share this article with someone who may find it helpful.
